Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Current Leases (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Current Leases for 5 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 13.94% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 13.94% increase, with the full-year FY2024 number at $1.6 million, down 3.17% from a year prior.
  • Current Leases was $1.5 million for Q3 2025 at Werewolf Therapeutics, up from $1.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.1 million in Q1 2023 to a low of $699000.0 in Q1 2021.
  • A 5-year average of $1.5 million and a median of $1.5 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: surged 171.51% in 2022, then tumbled 42.4% in 2024.
  • Werewolf Therapeutics' Current Leases stood at $1.1 million in 2021, then soared by 94.4% to $2.1 million in 2022, then decreased by 22.84% to $1.6 million in 2023, then fell by 3.17% to $1.6 million in 2024, then dropped by 3.4% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Current Leases are $1.5 million (Q3 2025), $1.5 million (Q2 2025), and $1.4 million (Q1 2025).